An anthracycline antibiotic that has formula C27H29NO11.
Chemical ID:
MESH:D004317
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside promotes the reaction [Doxorubicin results in increased expression of BCL2 protein]; 4-(((4-carboxybutyl) (2- (5-fluoro-2-((4'-(trifluoromethyl) biphenyl-4-yl)methoxy)phenyl)ethyl) amino)methyl)benzoic acid affects the reaction [Doxorubicin affects the expression of BCL2 protein]; [Doxorubicin co-treated with paeonol] results in increased expression of BCL2 mRNA; [Doxorubicin co-treated with ZFP260 protein] results in increased expression of BCL2 protein; Amlodipine inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Carvedilol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; Carvedilol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; caryophyllene inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Catechin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; Catechin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Chitosan analog inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; chloroquine diphosphate promotes the reaction [Doxorubicin inhibits the reaction [Thioacetamide results in increased expression of BCL2 mRNA]]; citronellal inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; coenzyme Q10 inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; corilagin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; corosolic acid inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; dapagliflozin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; diallyl trisulfide inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Doxorubicin inhibits the reaction [Thioacetamide results in increased expression of BCL2 mRNA]; Doxorubicin promotes the reaction [chloroquine diphosphate inhibits the reaction [Thioacetamide results in increased expression of BCL2 mRNA]]; Doxorubicin promotes the reaction [TP53 protein binds to BCL2 promoter]; Drugs, Chinese Herbal inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; EPO protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Exenatide inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; Febuxostat inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; geraniol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; GHRL protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; Ginkgo biloba extract inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; iodopravadoline inhibits the reaction [caryophyllene inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; Lithium Chloride inhibits the reaction [citronellal inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; Melatonin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Metformin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; morin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; necrostatin-1 inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Phenylephrine inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; pifithrin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; PRKAA2 protein promotes the reaction [corosolic acid inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; Proanthocyanidins inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; Proanthocyanidins inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Propofol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Quercetin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; Quercetin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; rhodioloside inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; salvianolic acid B inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; SC-66 compound inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; SIRT4 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Sitagliptin Phosphate inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; STAT3 protein promotes the reaction [dapagliflozin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; TDRG1 protein affects the reaction [Doxorubicin results in decreased expression of BCL2 protein]; TFEB protein promotes the reaction [corosolic acid inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; TNF protein affects the reaction [GHRL protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]]; U 0126 inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Valsartan inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Verteporfin inhibits the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; Vitamin E inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; Withanolides inhibits the reaction [Doxorubicin results in increased expression of BCL2 protein]; YAP1 protein affects the reaction [Melatonin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]
[Zoledronic Acid co-treated with Doxorubicin] results in decreased expression of BCL2 protein; BDKRB1 protein affects the reaction [Doxorubicin results in decreased expression of BCL2 protein]; corosolic acid inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Doxorubicin inhibits the reaction [Quercetin results in decreased expression of BCL2 protein]; Doxorubicin promotes the reaction [Hesperidin results in decreased expression of BCL2 mRNA]; Doxycycline inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Exenatide inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; Genistein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Nanotubes, Carbon inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; PSMB10 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; PSMB8 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; PSMB9 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Resveratrol affects the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Resveratrol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; SC-66 compound inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; Sildenafil Citrate inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; SIRT4 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Tadalafil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; zinc chloride inhibits the reaction [Doxorubicin results in increased expression of BCL2 mRNA]; zinc protoporphyrin inhibits the reaction [Resveratrol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]
[[[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased phosphorylation of ABL1 protein] which results in increased expression of TP73 protein] which results in decreased expression of BCL2 protein; [[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in decreased expression of BCL2 mRNA; [[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein] which results in decreased expression of BCL2 protein; [[F3 protein co-treated with F7 protein] results in increased expression of BCL2 protein] which results in decreased susceptibility to Doxorubicin; [Amifostine co-treated with Doxorubicin] results in decreased expression of BCL2 mRNA; [Arsenic Trioxide co-treated with Doxorubicin co-treated with Magnetite Nanoparticles analog] affects the expression of BCL2 mRNA; [Arsenic Trioxide co-treated with Doxorubicin co-treated with Magnetite Nanoparticles analog] affects the expression of BCL2 protein; [Doxorubicin co-treated with bisphenol A] results in increased expression of BCL2 protein; [Doxorubicin co-treated with Curcumin] results in decreased expression of BCL2 mRNA; [Doxorubicin co-treated with Cyclophosphamide] affects the expression of BCL2 mRNA; [Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; [Doxorubicin co-treated with Melatonin] results in decreased expression of BCL2 protein; [Doxorubicin co-treated with Resveratrol] results in decreased expression of BCL2 mRNA; [Doxorubicin co-treated with Resveratrol] results in decreased expression of BCL2 protein; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BCL2 protein; [Estradiol results in increased expression of BCL2 mRNA] which results in increased susceptibility to Doxorubicin; [F3 protein affects the expression of BCL2 protein] which affects the susceptibility to Doxorubicin; [germacrone results in increased susceptibility to Doxorubicin] which results in decreased expression of BCL2; [Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of BCL2 mRNA; [YAP1 protein promotes the reaction [[Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased expression of TP73 protein]] which results in decreased expression of BCL2 protein; Acetylcysteine inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of and results in increased activity of and results in increased localization of BID protein]]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP9 protein]]; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased expression of and results in increased activity of BAX protein]]; BCL2 protein inhibits the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of and results in increased activity of and results in increased localization of BID protein]]; BCL2 protein inhibits the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]; BCL2 protein inhibits the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]]; BCL2 protein inhibits the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP9 protein]]; BCL2 protein inhibits the reaction [PI103 promotes the reaction [Doxorubicin results in increased expression of and results in increased activity of BAX protein]]; BCL2 protein results in decreased susceptibility to [Doxorubicin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one]; BCL2 protein results in decreased susceptibility to [Doxorubicin co-treated with PI103]; Doxorubicin promotes the reaction [Melatonin results in decreased expression of BCL2 mRNA]; Doxorubicin promotes the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]; Folic Acid inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; GSTA1 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; HIF1A protein affects the reaction [IL6 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; IFNA1 protein promotes the reaction [Doxorubicin results in decreased expression of BCL2 protein]; IL6 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; Loperamide promotes the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; Morphine inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; NORAD inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; pluronic block copolymer p85 inhibits the reaction [Doxorubicin results in increased expression of BCL2 mRNA]; PRKAR2B protein inhibits the reaction [TDRG1 protein affects the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BCL2 protein]; Tamoxifen promotes the reaction [Doxorubicin results in increased expression of BCL2 mRNA]